Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study
ABSTRACTTo illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantita...
Gespeichert in:
| Veröffentlicht in: | Clinical nuclear medicine 2014-03, Vol.39 (3), p.e227-e228 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e228 |
|---|---|
| container_issue | 3 |
| container_start_page | e227 |
| container_title | Clinical nuclear medicine |
| container_volume | 39 |
| creator | Gamez, Josep Lorenzo-Bosquet, Carles Cuberas-Borrós, Gemma Carmona, Francesc Badía, Mercedes Castilló, Joaquin de Fabregues, Oriol Hernández-Vara, Jorge Castell-Conesa, Joan |
| description | ABSTRACTTo illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies. |
| doi_str_mv | 10.1097/RLU.0b013e31828162cd |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1494303735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1494303735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445d-e2aa1101b85bf71a465f61e2c24602e3c6006f88be744f2b39cdf551e54e7f813</originalsourceid><addsrcrecordid>eNp9kFFr2zAUhcXYWNO0_2AMPe5Fra4ky_beStq0gcBCmzyUUoxsX6faHMuT7KX593VIuoc97OmeA-ecCx8hX4BfAE_jy_v56oLnHCRKSEQCWhTlBzKCSGrGhUg_khGXWrI01uKEnIbwk3PQoNVnciJkJCGWakReF96tPYZg_yBdDGLXmLazBb12rdnYBv16b7BDb503nXUNtQ2965vONutucNc2oAn4nV7RJxBy9symCzaZLenD4maypMutY49oPJ26unZbtmrpQ9eXuzPyqTJ1wPPjHZPV9GY5uWPzH7ezydWcFUpFJUNhDACHPInyKgajdFRpQFEIpblAWWjOdZUkOcZKVSKXaVFWUQQYKYyrBOSYfDvstt797jF02caGAuvaNOj6kIFKleQyHoiMiTpEC-9C8Fhlrbcb43cZ8GzPPBuYZ_8yH2pfjx_6fIPl39I75CGQHAJbVw8cw6-636LPXtDU3cv_t98AcDGPQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1494303735</pqid></control><display><type>article</type><title>Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Gamez, Josep ; Lorenzo-Bosquet, Carles ; Cuberas-Borrós, Gemma ; Carmona, Francesc ; Badía, Mercedes ; Castilló, Joaquin ; de Fabregues, Oriol ; Hernández-Vara, Jorge ; Castell-Conesa, Joan</creator><creatorcontrib>Gamez, Josep ; Lorenzo-Bosquet, Carles ; Cuberas-Borrós, Gemma ; Carmona, Francesc ; Badía, Mercedes ; Castilló, Joaquin ; de Fabregues, Oriol ; Hernández-Vara, Jorge ; Castell-Conesa, Joan</creatorcontrib><description>ABSTRACTTo illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies.</description><identifier>ISSN: 0363-9762</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/RLU.0b013e31828162cd</identifier><identifier>PMID: 23531734</identifier><language>eng</language><publisher>United States: by Lippincott Williams & Wilkins</publisher><subject>Dopaminergic Neurons - pathology ; Follow-Up Studies ; Humans ; Huntington Disease - diagnostic imaging ; Huntington Disease - pathology ; Male ; Middle Aged ; Synapses - pathology ; Tomography, Emission-Computed, Single-Photon ; Tropanes</subject><ispartof>Clinical nuclear medicine, 2014-03, Vol.39 (3), p.e227-e228</ispartof><rights>2014 by Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c445d-e2aa1101b85bf71a465f61e2c24602e3c6006f88be744f2b39cdf551e54e7f813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23531734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gamez, Josep</creatorcontrib><creatorcontrib>Lorenzo-Bosquet, Carles</creatorcontrib><creatorcontrib>Cuberas-Borrós, Gemma</creatorcontrib><creatorcontrib>Carmona, Francesc</creatorcontrib><creatorcontrib>Badía, Mercedes</creatorcontrib><creatorcontrib>Castilló, Joaquin</creatorcontrib><creatorcontrib>de Fabregues, Oriol</creatorcontrib><creatorcontrib>Hernández-Vara, Jorge</creatorcontrib><creatorcontrib>Castell-Conesa, Joan</creatorcontrib><title>Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study</title><title>Clinical nuclear medicine</title><addtitle>Clin Nucl Med</addtitle><description>ABSTRACTTo illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies.</description><subject>Dopaminergic Neurons - pathology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Huntington Disease - diagnostic imaging</subject><subject>Huntington Disease - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Synapses - pathology</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><subject>Tropanes</subject><issn>0363-9762</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFFr2zAUhcXYWNO0_2AMPe5Fra4ky_beStq0gcBCmzyUUoxsX6faHMuT7KX593VIuoc97OmeA-ecCx8hX4BfAE_jy_v56oLnHCRKSEQCWhTlBzKCSGrGhUg_khGXWrI01uKEnIbwk3PQoNVnciJkJCGWakReF96tPYZg_yBdDGLXmLazBb12rdnYBv16b7BDb503nXUNtQ2965vONutucNc2oAn4nV7RJxBy9symCzaZLenD4maypMutY49oPJ26unZbtmrpQ9eXuzPyqTJ1wPPjHZPV9GY5uWPzH7ezydWcFUpFJUNhDACHPInyKgajdFRpQFEIpblAWWjOdZUkOcZKVSKXaVFWUQQYKYyrBOSYfDvstt797jF02caGAuvaNOj6kIFKleQyHoiMiTpEC-9C8Fhlrbcb43cZ8GzPPBuYZ_8yH2pfjx_6fIPl39I75CGQHAJbVw8cw6-636LPXtDU3cv_t98AcDGPQA</recordid><startdate>201403</startdate><enddate>201403</enddate><creator>Gamez, Josep</creator><creator>Lorenzo-Bosquet, Carles</creator><creator>Cuberas-Borrós, Gemma</creator><creator>Carmona, Francesc</creator><creator>Badía, Mercedes</creator><creator>Castilló, Joaquin</creator><creator>de Fabregues, Oriol</creator><creator>Hernández-Vara, Jorge</creator><creator>Castell-Conesa, Joan</creator><general>by Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201403</creationdate><title>Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study</title><author>Gamez, Josep ; Lorenzo-Bosquet, Carles ; Cuberas-Borrós, Gemma ; Carmona, Francesc ; Badía, Mercedes ; Castilló, Joaquin ; de Fabregues, Oriol ; Hernández-Vara, Jorge ; Castell-Conesa, Joan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445d-e2aa1101b85bf71a465f61e2c24602e3c6006f88be744f2b39cdf551e54e7f813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Dopaminergic Neurons - pathology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Huntington Disease - diagnostic imaging</topic><topic>Huntington Disease - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Synapses - pathology</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><topic>Tropanes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gamez, Josep</creatorcontrib><creatorcontrib>Lorenzo-Bosquet, Carles</creatorcontrib><creatorcontrib>Cuberas-Borrós, Gemma</creatorcontrib><creatorcontrib>Carmona, Francesc</creatorcontrib><creatorcontrib>Badía, Mercedes</creatorcontrib><creatorcontrib>Castilló, Joaquin</creatorcontrib><creatorcontrib>de Fabregues, Oriol</creatorcontrib><creatorcontrib>Hernández-Vara, Jorge</creatorcontrib><creatorcontrib>Castell-Conesa, Joan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gamez, Josep</au><au>Lorenzo-Bosquet, Carles</au><au>Cuberas-Borrós, Gemma</au><au>Carmona, Francesc</au><au>Badía, Mercedes</au><au>Castilló, Joaquin</au><au>de Fabregues, Oriol</au><au>Hernández-Vara, Jorge</au><au>Castell-Conesa, Joan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study</atitle><jtitle>Clinical nuclear medicine</jtitle><addtitle>Clin Nucl Med</addtitle><date>2014-03</date><risdate>2014</risdate><volume>39</volume><issue>3</issue><spage>e227</spage><epage>e228</epage><pages>e227-e228</pages><issn>0363-9762</issn><eissn>1536-0229</eissn><abstract>ABSTRACTTo illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies.</abstract><cop>United States</cop><pub>by Lippincott Williams & Wilkins</pub><pmid>23531734</pmid><doi>10.1097/RLU.0b013e31828162cd</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9762 |
| ispartof | Clinical nuclear medicine, 2014-03, Vol.39 (3), p.e227-e228 |
| issn | 0363-9762 1536-0229 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1494303735 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Dopaminergic Neurons - pathology Follow-Up Studies Humans Huntington Disease - diagnostic imaging Huntington Disease - pathology Male Middle Aged Synapses - pathology Tomography, Emission-Computed, Single-Photon Tropanes |
| title | Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease: A [123I]-FP-CIT SPECT Two-Year Follow-Up Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T14%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20Presynaptic%20Dopaminergic%20Deterioration%20in%20Huntington%20Disease:%20A%20%5B123I%5D-FP-CIT%20SPECT%20Two-Year%20Follow-Up%20Study&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=Gamez,%20Josep&rft.date=2014-03&rft.volume=39&rft.issue=3&rft.spage=e227&rft.epage=e228&rft.pages=e227-e228&rft.issn=0363-9762&rft.eissn=1536-0229&rft_id=info:doi/10.1097/RLU.0b013e31828162cd&rft_dat=%3Cproquest_cross%3E1494303735%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1494303735&rft_id=info:pmid/23531734&rfr_iscdi=true |